Scholarlink

Background <p>Whole-genome sequencing has enabled the development of a wide range of analytical tools to search for abnormalities associated with tumors. As classic myeloproliferative neoplasms (MPNs) are associated with genomic alterations in hematopoietic stem cells, the World Health Organization (WHO) recommendations include since 2008 molecular investigations as an important part of the diagnosis and management of these pathologies. Recent advances in sequencing technologies, such as next-generation sequencing (NGS), have enhanced the analysis platforms. However, epidemiological information on MPNs is limited, especially in low/middle-income countries.</p> Aim <p>This literature review provides a state-of-the-art on the classification of MPNs and a comprehensive examination of contemporary analytical techniques, while highlighting the advantages and drawbacks of each method.</p> Methods <p>The scientific literature for the synthesis of this article was obtained by searching the PubMed and Science Direct databases, and the tables were generated using Excel 2016 software.</p> Results <p>Driver mutations in MPNs can be detected by genotyping or sequencing. Genotyping techniques present an increased risk of false negatives because of their low sensitivity, whereas sequencing techniques are more sensitive but can present specificity or time-consuming disadvantages.</p> Conclusion <p>Although a large number of applications favor NGS, it is essential to consider the cost-effectiveness of these technologies to meet the needs of laboratories in low/middle-income regions. Alternative techniques such as real-time polymerase chain reaction (qPCR), immunohistochemistry (CAL2IHC), and liquid chromatography (dHPLC) should be explored and considered as sustainable options.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The molecular management of classic myeloproliferative neoplasm

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Charlène G. S. Soro,
  • Sara Benchikh,
  • Adil El Hamouchi,
  • Imane Morjane,
  • Rachid Saile,
  • Halima Lebrazi,
  • Sanaa Nassereddine

摘要

Background

Whole-genome sequencing has enabled the development of a wide range of analytical tools to search for abnormalities associated with tumors. As classic myeloproliferative neoplasms (MPNs) are associated with genomic alterations in hematopoietic stem cells, the World Health Organization (WHO) recommendations include since 2008 molecular investigations as an important part of the diagnosis and management of these pathologies. Recent advances in sequencing technologies, such as next-generation sequencing (NGS), have enhanced the analysis platforms. However, epidemiological information on MPNs is limited, especially in low/middle-income countries.

Aim

This literature review provides a state-of-the-art on the classification of MPNs and a comprehensive examination of contemporary analytical techniques, while highlighting the advantages and drawbacks of each method.

Methods

The scientific literature for the synthesis of this article was obtained by searching the PubMed and Science Direct databases, and the tables were generated using Excel 2016 software.

Results

Driver mutations in MPNs can be detected by genotyping or sequencing. Genotyping techniques present an increased risk of false negatives because of their low sensitivity, whereas sequencing techniques are more sensitive but can present specificity or time-consuming disadvantages.

Conclusion

Although a large number of applications favor NGS, it is essential to consider the cost-effectiveness of these technologies to meet the needs of laboratories in low/middle-income regions. Alternative techniques such as real-time polymerase chain reaction (qPCR), immunohistochemistry (CAL2IHC), and liquid chromatography (dHPLC) should be explored and considered as sustainable options.